Teva Pharmaceutical Industries (NYSE:TEVA) Reaches New 1-Year High on Better-Than-Expected Earnings

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) shares hit a new 52-week high during mid-day trading on Thursday following a better than expected earnings announcement. The stock traded as high as $33.43 and last traded at $32.5270, with a volume of 2202319 shares trading hands. The stock had previously closed at $33.21.

The company reported $0.96 earnings per share for the quarter, beating the consensus estimate of $0.65 by $0.31. The firm had revenue of $4.71 billion during the quarter, compared to the consensus estimate of $4.36 billion. Teva Pharmaceutical Industries had a return on equity of 46.13% and a net margin of 4.24%.Teva Pharmaceutical Industries’s quarterly revenue was up 11.4% on a year-over-year basis. During the same period last year, the business posted $0.71 EPS. Teva Pharmaceutical Industries has set its FY 2026 guidance at 2.570-2.770 EPS.

Teva Pharmaceutical Industries News Summary

Here are the key news stories impacting Teva Pharmaceutical Industries this week:

• Positive Sentiment: Q4 results materially beat expectations — Teva reported $0.96 EPS vs. $0.65 consensus and revenue of $4.71B vs. $4.36B expected; revenue rose ~11% YoY, signaling durable top-line strength. Teva Q4 earnings release and call materials
• Positive Sentiment: Profit uptick driven by branded drug sales and a milestone payment tied to a late?stage study — this extra revenue helped lift quarterly profit and underscores pipeline monetization potential. Reuters: Teva profit, revenue rise in fourth quarter
• Positive Sentiment: Company emphasizes three consecutive years of revenue growth and an “innovative” pipeline poised to unlock value — helpful for investor sentiment around long?term growth potential. GlobeNewswire: Teva growth and pipeline PR
• Positive Sentiment: Analyst commentary highlights TEVA as an attractive value/quality combination based on recent results and style scores — may attract value-oriented flows. Zacks: Why Teva is a strong value stock
• Neutral Sentiment: Earnings call transcript now available for detail on management commentary, volume dynamics, and pipeline timing — useful for modeling but no new headline surprises in transcript. Seeking Alpha: Q4 2025 earnings call transcript
• Neutral Sentiment: Analyst note on Q4 key metrics provides context (ROE, margins, YoY comparisons) to help refine forecasts — useful for model adjustments but not headline-moving by itself. Zacks: Q4 key metrics analysis
• Neutral Sentiment: Marketing/awareness effort: Teva partnered on a Huntington’s disease awareness campaign (Will Forte) — positive for reputation and patient engagement but unlikely to move near-term revenue materially. Yahoo Finance: Will Forte joins Teva campaign
• Negative Sentiment: FY2026 guidance came in slightly below consensus: EPS of $2.570–$2.770 (consensus ~2.71) and revenue guidance $16.4B–$16.8B vs. ~$17.0B consensus — this guidance gap is the principal near?term risk and explains some downward pressure in reaction. GlobeNewswire: FY2026 guidance

Wall Street Analysts Forecast Growth

Several research analysts have recently commented on the company. The Goldman Sachs Group boosted their target price on Teva Pharmaceutical Industries from $31.00 to $35.00 and gave the stock a “buy” rating in a report on Friday, December 19th. Truist Financial boosted their price target on Teva Pharmaceutical Industries from $36.00 to $38.00 and gave the company a “buy” rating in a report on Thursday. Jefferies Financial Group upped their target price on Teva Pharmaceutical Industries from $29.00 to $40.00 and gave the stock a “buy” rating in a report on Tuesday, January 6th. Wall Street Zen lowered Teva Pharmaceutical Industries from a “strong-buy” rating to a “buy” rating in a report on Sunday, January 18th. Finally, Scotiabank upped their price objective on Teva Pharmaceutical Industries from $35.00 to $40.00 and gave the company a “sector outperform” rating in a report on Thursday. Two analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, Teva Pharmaceutical Industries currently has a consensus rating of “Buy” and an average target price of $35.67.

Insiders Place Their Bets

In other news, Director Roberto Mignone sold 77,400 shares of Teva Pharmaceutical Industries stock in a transaction dated Tuesday, December 16th. The stock was sold at an average price of $30.24, for a total value of $2,340,576.00. Following the transaction, the director owned 367,600 shares in the company, valued at approximately $11,116,224. The trade was a 17.39% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP Richard Daniell sold 115,468 shares of the stock in a transaction that occurred on Tuesday, December 9th. The stock was sold at an average price of $28.68, for a total value of $3,311,622.24. Following the completion of the sale, the vice president owned 48,384 shares of the company’s stock, valued at approximately $1,387,653.12. This trade represents a 70.47% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 622,060 shares of company stock worth $17,076,965 over the last three months. Corporate insiders own 0.55% of the company’s stock.

Hedge Funds Weigh In On Teva Pharmaceutical Industries

Several institutional investors have recently bought and sold shares of the stock. AQR Capital Management LLC increased its position in shares of Teva Pharmaceutical Industries by 24.6% during the 1st quarter. AQR Capital Management LLC now owns 23,955 shares of the company’s stock valued at $368,000 after purchasing an additional 4,732 shares during the last quarter. Focus Partners Wealth boosted its stake in shares of Teva Pharmaceutical Industries by 4.5% during the 1st quarter. Focus Partners Wealth now owns 40,074 shares of the company’s stock worth $616,000 after purchasing an additional 1,739 shares during the period. GAMMA Investing LLC grew its holdings in Teva Pharmaceutical Industries by 65.9% during the 2nd quarter. GAMMA Investing LLC now owns 7,282 shares of the company’s stock valued at $122,000 after purchasing an additional 2,892 shares during the last quarter. Signaturefd LLC lifted its stake in Teva Pharmaceutical Industries by 45.0% in the second quarter. Signaturefd LLC now owns 9,814 shares of the company’s stock worth $164,000 after purchasing an additional 3,046 shares during the last quarter. Finally, Sound Income Strategies LLC boosted its position in shares of Teva Pharmaceutical Industries by 3,715.8% during the second quarter. Sound Income Strategies LLC now owns 2,900 shares of the company’s stock valued at $49,000 after buying an additional 2,824 shares during the period. 54.05% of the stock is owned by hedge funds and other institutional investors.

Teva Pharmaceutical Industries Stock Performance

The company has a quick ratio of 0.82, a current ratio of 1.11 and a debt-to-equity ratio of 2.31. The stock has a market cap of $37.59 billion, a P/E ratio of 54.21, a PEG ratio of 1.85 and a beta of 0.66. The business has a 50 day moving average price of $30.12 and a 200 day moving average price of $22.96.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.